Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1994;31(2-3):301-7.
doi: 10.1007/BF00666162.

Antiestrogen resistance in ER positive breast cancer cells

Affiliations
Review

Antiestrogen resistance in ER positive breast cancer cells

S Paik et al. Breast Cancer Res Treat. 1994.

Abstract

Acquisition of the antiestrogen resistance by breast cancer cells in vivo may result from a variety of mechanisms. The main pathway appears to involve loss of estrogen receptor (ER) expression or selection for ER negative cells among heterogenous population of tumor cells. However, clinical data suggest that, in about 30% of the cases, antiestrogen resistance arises even in the presence of estrogen receptors. Postulated mechanisms leading to the latter phenotype include selection for variant receptor forms during treatment, development of novel metabolic pathways for the drug, loss of nuclear co-factors, or activation of signal transduction pathway that cross activate ER signals. We have used an in vitro experimental system utilizing LY-2 cell line, an ER positive and antiestrogen resistant MCF-7 cell variant, to study the mechanism of antiestrogen resistance in the presence of functional ER. Result from a complementation experiment suggests that LY-2 phenotype is a recessive trait. Cloning of the genetic defect in the LY-2 cells would provide further insight for the mechanism of antiestrogen resistance in ER positive breast cancer cells.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Cancer Res. 1986 Apr;46(4 Pt 2):1904-8 - PubMed
    1. Cancer Res. 1992 Aug 1;52(15):4106-12 - PubMed
    1. Cancer Res. 1991 Jan 1;51(1):105-9 - PubMed
    1. Breast Cancer Res Treat. 1993;26(3):237-46 - PubMed
    1. Mol Endocrinol. 1991 Nov;5(11):1571-7 - PubMed

MeSH terms

LinkOut - more resources